Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Aubrey V. Tembo"'
Publikováno v:
Steroids. 28:387-403
An extensive survey of radioimmunoassay calibration data for prednisolone, prednisone and digoxin indicated that the common practice of preparing calibration curves with individual subject's pre-dose plasma or serum, and using this to estimate unknow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90b2ca04ead3e396caf13ad4326c6592
https://doi.org/10.1016/0039-128x(76)90048-9
https://doi.org/10.1016/0039-128x(76)90048-9
Publikováno v:
Steroids. 29:679-693
A comparison was made between plasma concentrations of prednisolone measured by both competitive protein binding radioassay (CPB) and radioimmunoassay (RIA) and, with each assay, using a calibration curve generated from individual subject data and fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af77ff7a7af311325b8658e23100bc1e
https://doi.org/10.1016/0039-128x(77)90019-8
https://doi.org/10.1016/0039-128x(77)90019-8
Autor:
John G. Wagner, B S Ermelinda Sakmar, Donald J. Weidler, Aubrey V. Tembo, Margarette R. Hallmark
Publikováno v:
The Journal of Clinical Pharmacology. 16:620-624
Two commercial prednisone tablets were studied which had previously been shown by Sullivan et al.5,6 to have the slowest and fastest in vitro rates of dissolution, and the slowest and fastest rise to peak plasma prednisolone concentrations in human b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dba81e9ce7e446c86f29006be8596da
https://doi.org/10.1002/j.1552-4604.1976.tb01500.x
https://doi.org/10.1002/j.1552-4604.1976.tb01500.x
Publikováno v:
Journal of pharmacokinetics and biopharmaceutics. 5(3)
Two fourtreatment crossover studies were performed using 12 adult male volunteers in each with seven different commercially available prednisolone tablets. Plasma samples were assayed for prednisolone by a radioimmunoassay method. Statisacal analyses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb3b507a1340519544706b081ba75cf7
https://pubmed.ncbi.nlm.nih.gov/577932
https://pubmed.ncbi.nlm.nih.gov/577932
Publikováno v:
Journal of pharmaceutical sciences. 62(12)
Nitrofurantoin, l-[(5-nitrofurfurylidene)amino] hydantoin, is an antibacterial agent used clinically to treat specific urinary tract infections. Physiocochemically, the drug is a weak acid (pKa 7.2) possessing relatively low aqueous solubility charac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::785533fb72d60a49653fdb6021a96de5
https://pubmed.ncbi.nlm.nih.gov/4762187
https://pubmed.ncbi.nlm.nih.gov/4762187
Autor:
TEMBO, AUBREY V., SAKMAR, ERMELINDA, HALLMARK, MARGARETTE R., WEIDLER, DONALD J., WAGNER, JOHN G.
Publikováno v:
Journal of Clinical Pharmacology; Nov1976, Vol. 16 Issue 11, p620-624, 5p
Publikováno v:
In Journal of Pharmaceutical Sciences September 1975 64(9):1475-1481